The abstract is read at the publisher; the summary is JClub's.
A consensus IgG4-related disease treatment guideline was developed from 28 graded statements, reaching agreement on 22 statements by 52 physicians.
- Why it matters: Treatment decisions needed updated, evidence-based guidance after the 2015 consensus, as new phase 3 randomized placebo-controlled trials emerged and the literature expanded.
- What they did: A geographically and professionally diverse group generated 183 candidate questions, narrowed to 40, then used a systematic literature search to draft 28 treatment statements with Oxford Levels of Evidence grading.
- The result: The resulting guidelines synthesize recent trial-driven progress while showing that most statements still rest on low-level evidence, highlighting knowledge gaps for future research.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.